Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
Status:
Terminated
Trial end date:
2015-04-28
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate efficacy and safety of the combination of lenalidomide,
an immunomodulatory drug (IMiD) with a standard immunochemotherapy treatment, called R-DHAP.
R-DHAP consists of a monoclonal antibody called Rituximab and chemotherapy consisting of
Dexamethasone, high dose Cytarabine, often called Ara-C, and platinum based chemotherapy,
either cisplatinum, or, if treatment with cisplatinum is contraindicated, carboplatinum.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH